We have a consolidated scientific track record with international recognition in advanced cell therapy medicinal products using cultured mesenchymal cells (CMC).
This work has resulted in publications in international journals indexed in PubMed/MEDLINE, Scopus and Web of Science, with over 1,000 cumulative citations in the specialized scientific literature.
ITRT’s evidence comes from clinical trials and clinical series published in peer-reviewed journals, mainly in knee osteoarthritis, patellar tendinopathy, lumbar degenerative disc disease and atrophic non-union. Most are small phase I/II studies: they show a good safety profile and clinical and structural improvements on imaging, but their results cannot be extrapolated to every patient or to other indications.
Author: Dr Robert Soler, Medical Director of ITRT. Updated 12 October 2026.
| Indication | Study | Design and patients | Main finding | Registration |
|---|---|---|---|---|
| Chronic patellar tendinopathy | Rodas et al., Am J Sports Med, 2021 (PMID 33783227) | Phase 1/2, randomized, double-blind, active control; 20 patients | At 6 months, pain and function improved in both groups with no difference between them; tendon structure improved significantly more with CMC on ultrasound and MRI | EudraCT 2016-001262-28; NCT03454737 |
| Chronic patellar tendinopathy (follow-up) | Soler et al., Orthop J Sports Med, 2023 (PMID 37711505) | 12-month follow-up of the 20 patients, all treated with CMC | Clinical improvement and improved tendon structure on MRI maintained; no adverse events | Same trial |
| Chronic patellar tendinopathy (secondary analysis) | Ortega-Cebrián et al., Biomedicines, 2024 (PMID 39062172) | Secondary analysis of the same trial using ultrasound tissue characterization (UTC); 20 male patients | Better structural organization of the tendon in the CMC group at 3, 6 and 12 months | Same trial |
| Knee osteoarthritis | Orozco et al., Transplantation, 2013 (PMID 23680930) | Uncontrolled pilot study; 12 patients, autologous CMC | Safety and feasibility confirmed; improvement in pain and function at one year; improved cartilage quality on MRI (T2 mapping) in 11 of 12 patients | Not stated in the abstract |
| Knee osteoarthritis | Vega et al., Transplantation, 2015 (PMID 25822648) | Randomized; 30 patients, allogeneic CMC versus hyaluronic acid | Significant improvement in pain and function indices versus the control group; improved cartilage quality on T2 mapping | EudraCT 2011-005321-51; NCT01586312 |
| Knee osteoarthritis | Soler et al., Knee, 2016 (PMID 26783191) | Open-label, single-arm phase I-II; 15 patients | Well tolerated; sustained pain reduction; signs of cartilage repair on T2 mapping at 12 months | Not stated in the abstract |
| Lumbar degenerative disc disease | Orozco et al., Transplantation, 2011 (PMID 21792091) | Uncontrolled pilot study; 10 patients | Improvement in pain and disability; increased disc water content at 12 months, without recovery of disc height | Not stated in the abstract |
| Atrophic non-union of long bones | Orozco Delclós et al., J Transl Med, 2024 (PMID 38789992) | Open-label, multicenter phase 2; 12 patients, adipose-derived CMC combined with a biomaterial | Bone healing in 10 of 12 cases (83%); two procedure-related adverse events, in the same patient | EudraCT 2013-000930-37; NCT02483364 |
| Chronic Achilles tendon rupture | Soler-Rich et al., J Orthop Sports Med, 2026 (DOI 10.26502/josm.511500254) | Uncontrolled case series; 6 patients, minimum follow-up 24 months | Well tolerated; improvement in pain and function; structural tendon changes on MRI | Not stated |
Taken together, the published studies describe a favorable safety profile, clinical improvements and structural changes measurable on imaging in several indications. At the same time, most are small, phase I/II or uncontrolled studies, and in the only controlled tendon trial the improvement in pain and function at six months did not differ from the control group: the difference lay in tendon structure. An improvement on MRI or ultrasound does not, on its own, mean the tissue is identical to the original. For these reasons the results cannot be extrapolated to every patient or to other injuries.
Studies with a registration number can be looked up in the EU clinical trials register (EudraCT, replaced by CTIS for new trials) and on ClinicalTrials.gov; the publications can be found on PubMed through their PMID. A trial being authorized and registered means it was carried out under regulatory and ethics oversight, not that the medicine holds a marketing authorization.
See also: What are cultured mesenchymal cells (CMC)? · Which cell-based treatments can be considered legal and regenerative?
A prospective series of patients with chronic Achilles tendon rupture treated with ex vivo expanded autologous cultured mesenchymal cells (CMC). The study provides the first published data on the use of this advanced cell therapy medicinal product in this indication.
A pilot trial in 12 patients with knee osteoarthritis treated with an advanced cell therapy medicinal product based on autologous bone marrow-derived cultured mesenchymal cells (CMC). The study confirmed the safety of the procedure and showed clinical improvement at 12 months, with MRI findings compatible with changes in articular cartilage.
The 24-month follow-up of the pilot trial confirmed that improvements obtained with autologous cultured mesenchymal cells (CMC) were maintained over time. Patients preserved improvements in pain and functional capacity without further interventions, supporting the hypothesis of a sustained regenerative effect.
This multicenter trial compared allogeneic cultured mesenchymal cells (donor-derived) with hyaluronic acid in 30 patients with moderate knee osteoarthritis. Results showed significantly superior clinical improvement in the CMC group, with a favorable safety profile, opening the path to the use of allogeneic advanced cell therapy medicinal products.
With the largest published series at that time, we documented clinical and MRI results in 50 patients treated with autologous CMC expanded in a GMP cleanroom, in collaboration with IBGM. Findings showed consistent functional improvement and MRI signal changes compatible with articular cartilage regeneration at one year of follow-up.
The publication of the final results of the phase I-II trial, with Dr. Soler as first author, closed the knee osteoarthritis series we initiated in 2013. The study confirmed the long-term safety of the advanced cell therapy medicinal product and provided imaging findings consistent with cartilage regeneration.
In collaboration with the FC Barcelona Clinic and Hospital Dexeus, we published the complete protocol of the phase I/II trial comparing autologous cultured mesenchymal cells with platelet-rich plasma (PRP) in patients with severe chronic patellar tendinopathy. The double-blind design with active control constitutes one of the most rigorous methodological standards in clinical research involving biological treatments.
Preliminary results at 6 months of the double-blind trial documented clinical improvements and structural changes in the patellar tendon in patients treated with autologous CMC, particularly in tendons with partial rupture greater than 3 mm. The findings provided the first evidence of structural changes in the tendon documented through imaging techniques with this type of medicinal product.
With Dr. Soler as first author, we present the complete results of the phase 1/2 trial at 12 months of follow-up. The study confirmed the safety profile of the advanced cell therapy medicinal product and documented sustained clinical benefits in patients with chronic patellar tendinopathy who had not responded to previous treatments.
A secondary analysis of the double-blind trial evaluated structural changes in the patellar tendon using imaging techniques in both treatment groups. Results showed that CMC produced more significant tissue modifications than PRP, providing objective evidence of structural regeneration beyond subjective clinical improvement.
We published the results of the first pilot trial demonstrating the feasibility and safety of treating degenerative intervertebral disc disease with autologous cultured mesenchymal cells. Follow-up MRI scans showed signs of disc rehydration, a marker of structural regeneration, in the treated patients.
Our team published a first scientific communication on the use of cultured mesenchymal cells (CMC) in post-radiotherapy xerostomia. The work proposed an approach based on glandular regeneration, differentiated from conventional symptomatic treatments.
In collaboration with Cochrane Spain, the FC Barcelona Clinic and the CAR, we documented evidence on the efficacy of autologous platelet-rich plasma in muscle ruptures with hematoma. The double-blind, placebo-controlled design represents a level of methodological rigour uncommon in biological treatments for acute sports injuries.
We published the results of a multicenter phase II trial in atrophic non-union of long bones. The study demonstrated a favorable safety profile and clinically relevant bone consolidation outcomes with mesenchymal cells expanded from adipose tissue combined with tricalcium phosphate.
in international peer-reviewed scientific journals
accumulated in the specialized scientific literature
with published evidence: knee osteoarthritis, patellar tendinopathy, lumbar disc disease, xerostomia, muscle injury and atrophic non-union
14 of them authorized clinical trials in patients
Publications in international peer-reviewed journals and accumulated citations are an objective way to validate the strength, visibility and impact of a scientific track record.